<div id="readability-page-1"><div><p>Over the last 7 days, the United States market has remained flat, yet it has seen a significant rise of 28% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.</p><h3>Top 10 Undervalued Stocks Based On Cash Flows In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Current Price</strong></td><td><strong>Fair Value (Est)</strong></td><td><strong>Discount (Est)</strong></td></tr><tr><td>Unity Software (U)</td><td>$27.72</td><td>$55.28</td><td>49.9%</td></tr><tr><td>Travere Therapeutics (TVTX)</td><td>$44.91</td><td>$88.58</td><td>49.3%</td></tr><tr><td>Sea (SE)</td><td>$85.41</td><td>$169.85</td><td>49.7%</td></tr><tr><td>Genuine Parts (GPC)</td><td>$103.52</td><td>$199.62</td><td>48.1%</td></tr><tr><td>First Merchants (FRME)</td><td>$40.02</td><td>$77.51</td><td>48.4%</td></tr><tr><td>Fifth Third Bancorp (FITB)</td><td>$49.40</td><td>$94.92</td><td>48%</td></tr><tr><td>FB Financial (FBK)</td><td>$53.53</td><td>$103.19</td><td>48.1%</td></tr><tr><td>Chemung Financial (CHMG)</td><td>$65.75</td><td>$127.22</td><td>48.3%</td></tr><tr><td>AST SpaceMobile (ASTS)</td><td>$68.43</td><td>$132.99</td><td>48.5%</td></tr><tr><td>AbbVie (ABBV)</td><td>$208.16</td><td>$400.51</td><td>48%</td></tr></tbody></table></div><p>Click here to see the full list of 151 stocks from our Undervalued US Stocks Based On Cash Flows screener.</p><p>Let's uncover some gems from our specialized screener.</p><h2>Travere Therapeutics (TVTX)</h2><p><strong>Overview:</strong> Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases in the United States, with a market cap of $4.08 billion.</p><p><strong>Operations:</strong> The company generates revenue of $490.73 million from the development and commercialization of innovative therapies for rare kidney and metabolic diseases in the United States.</p><p><strong>Estimated Discount To Fair Value:</strong> 49.3%</p><p>Travere Therapeutics is trading at US$44.91, significantly below its estimated future cash flow value of US$88.58, suggesting it may be undervalued based on cash flows. The company reported Q1 2026 revenue of US$127.2 million, up from US$81.73 million a year ago, and reduced its net loss to US$37.1 million from US$41.23 million last year. With FDA approval for FILSPARI expanding its market potential, Travere's revenue is forecasted to grow at 20.3% annually, outpacing the broader U.S market growth expectations.</p><ul><li>In light of our recent growth report, it seems possible that Travere Therapeutics' financial performance will exceed current levels.</li><li>Get an in-depth perspective on Travere Therapeutics' balance sheet by reading our health report here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/8a367f73-a6f2-4b6f-b781-0538bd368fa3/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>TVTX Discounted Cash Flow as at May 2026</figcaption></figure><h2>CVR Energy (CVI)</h2><p><strong>Overview:</strong> CVR Energy, Inc. operates in the United States focusing on renewable fuels and petroleum refining and marketing, as well as nitrogen fertilizer manufacturing, with a market cap of $3.35 billion.</p><p><strong>Operations:</strong> The company generates revenue through its operations in renewable fuels, petroleum refining and marketing, and nitrogen fertilizer manufacturing in the United States.</p><p><strong>Estimated Discount To Fair Value:</strong> 28.3%</p><p>CVR Energy is trading at US$34.2, below its estimated future cash flow value of US$47.72, highlighting potential undervaluation based on cash flows. Despite a recent Q1 2026 net loss of US$192 million and earnings challenges, the company expects to become profitable within three years with high forecasted return on equity. However, revenue growth remains sluggish at 0.6% annually, trailing the broader U.S market's expectations of 11.2%.</p><ul><li>According our earnings growth report, there's an indication that CVR Energy might be ready to expand.</li><li>Navigate through the intricacies of CVR Energy with our comprehensive financial health report here.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/85096f12-bc2f-4422-bac7-9d19553b4370/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>CVI Discounted Cash Flow as at May 2026</figcaption></figure><h2>Unity Software (U)</h2><p><strong>Overview:</strong> Unity Software Inc. provides a platform for developing, deploying, and enhancing games and interactive experiences across various devices globally, with a market cap of approximately $11.84 billion.</p><p><strong>Operations:</strong> The company's revenue from Software Solutions is $1.85 billion.</p><p><strong>Estimated Discount To Fair Value:</strong> 49.9%</p><p>Unity Software, trading at US$27.72, is significantly undervalued compared to its estimated future cash flow value of US$55.28. Despite recent insider selling and a volatile share price, Unity's strategic moves—such as discontinuing the ironSource Ads Network and divesting Supersonic—aim to enhance revenue growth and margins. The extended partnership with Meta further strengthens its VR platform presence. Unity anticipates profitability within three years, with earnings forecasted to grow substantially at 62.95% annually.</p><ul><li>The growth report we've compiled suggests that Unity Software's future prospects could be on the up.</li><li>Unlock comprehensive insights into our analysis of Unity Software stock in this financial health report.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/81b649ee-0ebc-4d90-9c59-c6ef29110c9d/chart/dcf/query-dGhlbWU9bGlnaHQ"/><figcaption>U Discounted Cash Flow as at May 2026</figcaption></figure><h2>Next Steps</h2><ul><li>Reveal the 151 hidden gems among our Undervalued US Stocks Based On Cash Flows screener with a single click here.</li><li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li><li>Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.</li></ul><h2>Want To Explore Some Alternatives?</h2><ul><li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li><li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li><li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.      It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Travere Therapeutics might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

TVTX

<p>Three stocks are identified as trading significantly below their intrinsic value, presenting potential investment opportunities. Unity Software (U) is trading at $27.72, 49.9% below its estimated fair value of $55.28. Travere Therapeutics (TVTX) is at $44.91, 49.3% below its fair value of $88.58. CVR Energy (CVI) trades at $34.20, 28.3% below its estimated value of $47.72. These companies show promising growth potential, with expected earnings growth rates of 62.95% for Unity and 20.3% for Travere, despite current market challenges.</p>

Simplywall

Travere Therapeutics

Unity Software

CVR Energy

Genuine Parts

First Merchants

Fifth Third Bancorp

FB Financial

Chemung Financial

AST SpaceMobile

Abbvie

Meta Platforms

Fifth Third Bancorp Pref Share FITBO 4.95 Perp 09/30/24 K

FIFTH THIRD BANK PREF SHARE FITB V6.625 P12/31/49 I

Fifth Third Bancorp Pref Shares FITBM 6.875 Perp 10/01/30

Fifth Third Bancorp Depositary Shs B Ser A Repr 1/40 6 % Perp Pfd Registered Shs B Ser A

3 Stocks Estimated To Be Trading Up To 49.9% Below Intrinsic Value